NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $5.07 -0.10 (-1.93%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arbutus Biopharma Stock (NASDAQ:ABUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$5.05▼$5.1950-Day Range$4.29▼$5.2252-Week Range$3.50▼$5.45Volume4.77 million shsAverage Volume3.72 million shsMarket Capitalization$1.00 billionP/E Ratio6.42Dividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core. In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics. This LNP platform underpins the company’s RNAi assets and has been the foundation for collaborations with other biopharmaceutical organizations seeking efficient delivery systems for mRNA and RNA-based medicines. Arbutus’ focus on innovative delivery solutions complements its antiviral drug discovery capabilities, positioning it at the forefront of HBV research and development. Founded through the merger of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus maintains dual operations in Warminster, Pennsylvania, and Vancouver, British Columbia. The company’s leadership team combines experience in virology, lipid chemistry and pharmaceutical development, supporting strategic alliances with academic institutions and contract research organizations worldwide. Arbutus continues to engage with global regulatory authorities to advance its clinical trials and seeks partnerships to broaden the reach of its potential HBV therapies.AI Generated. May Contain Errors. Read More Arbutus Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreABUS MarketRank™: Arbutus Biopharma scored higher than 31% of companies evaluated by MarketBeat, and ranked 784th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingArbutus Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Arbutus Biopharma is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is 6.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.16.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is 6.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.16.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.65% of the float of Arbutus Biopharma has been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 15.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 8.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.19 News SentimentArbutus Biopharma has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest14 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABUS Stock News HeadlinesArbutus Biopharma Launches $230 Million Tender Offer for Common SharesAugust 24, 2026 | finance.yahoo.comArbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common SharesAugust 24, 2026 | quiverquant.comQMajor Buy Alert Issued for August 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of August 31st. See which stocks his AI research platform is flagging right now.August 30 at 1:00 AM | TradeSmith (Ad)Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per ShareAugust 24, 2026 | globenewswire.comArbutus Biopharma (NASDAQ:ABUS) Declares Stock Buyback PlanAugust 23, 2026 | americanbankingnews.comArbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender OfferAugust 21, 2026 | quiverquant.comQArbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender OfferAugust 21, 2026 | globenewswire.comModerna’s Newfound War Chest Opens Door for 4 Strategic Acquisition TargetsAugust 20, 2026 | 247wallst.comSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $4.81 at the beginning of the year. Since then, ABUS stock has increased by 5.4% and is now trading at $5.07. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corporation (NASDAQ:ABUS) posted its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The biopharmaceutical company earned $1.01 million during the quarter, compared to analysts' expectations of $0.70 million. Arbutus Biopharma had a net margin of 84.22% and a trailing twelve-month return on equity of 90.98%. Is Arbutus Biopharma buying back stock? Arbutus Biopharma's board authorized a stock buyback plan on Friday, August 21st 2026, which permits the company to repurchase $0 in outstanding shares, according to EventVestor. This permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its stock is undervalued. Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's top institutional investors include Two Seas Capital LP (9.67%), Whitefort Capital Management LP (8.00%), BlackRock Inc. (6.97%) and Bank of America Corp DE (1.34%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA). Company Calendar Last Earnings8/13/2026Today8/30/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ABUS's financial health is in the Green zone, according to TradeSmith. ABUS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABUS CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees90Year Founded2005Price Target and Rating Average Price Target for Arbutus Biopharma$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside-1.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.79 Trailing P/E Ratio6.42 Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.50 million Net Margins84.22% Pretax Margin84.22% Return on Equity90.98% Return on Assets82.34% Debt Debt-to-Equity RatioN/A Current Ratio81.42 Quick Ratio81.42 Sales & Book Value Annual Sales$181.72 million Price / Sales5.53 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book3.87Miscellaneous Outstanding Shares198,106,000Free Float158,683,000Market Cap$1.00 billion OptionableOptionable Beta0.64 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ABUS) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredTrump’s new dollar decreeThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
